Table 4 CLL-directed therapy and COVID-19 management strategies according to thrombosis and bleeding status of CLL patients with COVID-19
Thrombosis | Bleeding | |||
|---|---|---|---|---|
No (n = 409) | Yes (n = 51) | No (n = 445) | Yes (n = 23) | |
On CLL treatment at the time of COVID-19 | 132/408 (32.4) | 21/51 (41.2) | 149/444 (32.7) | 11/23 (47.8) |
On treatment with corticosteroids for CLL or other disease | 46/397 (11.6) | 6/51 (11.8) | 49/432 (11.3) | 3/23 (13.0) |
Anti-CD20 at the time of COVID-19 | 27/406 (6.7) | 3/51 (5.9) | 25/442 (5.7) | 2/23 (8.7) |
Type of CLL treatment at the time of COVID-19 | ||||
BTKi only | 69/130 (53.1) | 10/21 (47.6) | 83/147 (56.5) | 4/11 (36.4) |
Venetoclax | 14/130 (10.8) | 4/21 (19.0) | 16/147 (10.9) | 4/11 (36.4) |
Venetoclax + Anti-CD20 | 11/130 (8.5) | 1/21 (4.8) | 9/147 (6.1) | 2/11 (18.2) |
PI3K inhibitors | 5/130 (3.8) | 0/21 (0.0) | 5/147 (3.4) | 0/11 (0) |
Anti-CD20 only | 4/130 (3.1) | 1/21 (4.8) | 4/147 (2.7) | 0/11 (0) |
Chemotherapy | 10/130 (7.7) | 2/21 (9.5) | 11/147 (7.5) | 1/11 (9.1) |
Chemoimmunotherapy | 12/130 (9.2) | 2/21 (9.5) | 13/147 (8.8) | 0/11 (0) |
BTKi + Venetoclax | 2/130 (1.5) | 0/21 (0.0) | 2/147 (1.4) | 0/11 (0) |
Steroids only | 3/130 (2.3) | 1/21 (4.8) | 4/147 (2.7) | 0/11 (0) |
Managing CLL treatment | ||||
Continued as planned | 25/131 (19.1) | 5/21 (23.8) | 30/148 (20.3) | 2/11 (18.2) |
Replaced with another treatment | 0/131 (0) | 1/21 (4.8) | 0/148 (0) | 1/11 (9.1) |
Stopped treatment | 106/131 (80.9) | 15//21 (71.4) | 118/148 (79.7) | 8/11 (72.7) |
Managing BTKi treatment | ||||
BTKi at the time of COVID-19 | 71/130 (54.6) | 10/21 (47.6) | 85/147 (57.8) | 4/11 (36.4) |
Continued BTKi as planned | 20/71 (28.2) | 3/10 (30.0) | 24/85 (28.2) | 1/4 (25.0) |
Stopped BTKi treatment | 51/71 (71.8) | 7/10 (70.0) | 61/85 (71.8) | 3/4 (75.0) |
Pharmacological treatment for COVID-19 | ||||
Convalescent hyperimmune plasma | 28/304 (9.2) | 5/37 (13.5) | 30/328 (9.1) | 5/18 (27.8)* |
Antivirals | 160/358 (44.7) | 24/45 (53.3) | 181/390 (46.4) | 9/22 (40.9) |
Hydroxychloroquine or similar | 139/356 (39.0) | 14/43 (32.6) | 150/385 (39.0) | 8/22 (36.4) |
Azithromycin | 143/351 (40.7) | 17/43 (39.5) | 158/380 (41.6) | 7/22 (31.8) |
Steroids | 320/390 (82.1) | 47/49 (95.9)* | 354/423 (83.7) | 21/23 (91.3) |
Anti-IL6 or anti-IL6R | 57/349 (16.3) | 19/45 (42.2)* | 70/380 (18.4) | 7/22 (31.8) |
ICU admission | 109/408 (26.7) | 27/51 (52.9)* | 128/444 (28.8) | 9/23 (39.1) |
Supportive therapy, ECMO | 2/409 (0.5) | 2/51 (3.9)* | 2/445 (0.4) | 2/23 (8.7)* |